Back to Search
Start Over
Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.
- Source :
- British Journal of Haematology; Jan2020, Vol. 188 Issue 2, p338-340, 3p, 1 Chart
- Publication Year :
- 2020
-
Abstract
- Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy (TMA) syndrome (Kremer et al. [8]). These three cases of TTP occurred during lenalidomide therapy (Table)- there was nothing that can usually be associated with thrombotic microangiopathy - no infectious trigger, no association with other autoimmune disorders, and no drugs intake. For our patients, the presence of anti-ADAMTS13 antibodies in each case and the efficacy of TPE and/or rituximab therapies imply an immune-mediated reaction. Montefusco et al. ([10]) described six autoimmune diseases after lenalidomide administration to 140 patients (4-3%): three autoimmune cytopenias and three organ-specific autoimmune disorders, occurring mostly in the first months of treatment. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 188
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 141250878
- Full Text :
- https://doi.org/10.1111/bjh.16333